Cross-Border Impact Ventures

Cross Border Impact Ventures is an impact investment firm based in Toronto, Canada, established in 2019. The firm focuses on investing in health technology companies that specifically address the needs of women, children, and adolescents. Cross Border Impact Ventures has collaborated with Grand Challenges Canada to create a platform aimed at redefining access to leading technologies. The firm primarily seeks investment opportunities in the health technology sector across the United States and Europe.

Megan Dover

Principal

Donna Parr

Managing Partner

Annie Theriault

Managing Partner

8 past transactions

Oxford Cancer Analytics

Series A in 2025
Oxford Cancer Analytics develops an AI-based platform for early cancer detection via blood testing. It analyzes liquid biopsy results from DNA, proteins, epigenetics, epidemiology, and medical history, enabling healthcare providers to identify cancers early and initiate curative treatment.

OncoLens

Series B in 2024
OncoLens develops a HIPAA-compliant platform that streamlines cancer treatment planning. It integrates disparate data sets, facilitates multidisciplinary discussions among oncology care teams, and automates accreditation processes to enable more informed clinical decisions.

Raydiant Oximetry

Series A in 2024
Raydiant Oximetry is a medical device company developing a non-invasive fetal monitoring device that measures fetal oxygen levels to improve outcomes for mothers and babies during childbirth and to reduce unnecessary cesarean sections. Founded in 2015 and based in California, the company aims to provide low-cost, real-time monitoring of fetal oxygenation during labor, enabling clinicians to assess fetal well-being and minimize intervention.

Axena Health

Series A in 2024
Axena Health is a company focused on improving the lives of women with pelvic floor disorders through digital technology. Its flagship product, Leva Pelvic Health System, is a prescription digital therapeutic offering at-home treatment for urinary and chronic fecal incontinence in women.

OncoLens

Venture Round in 2023
OncoLens develops a HIPAA-compliant platform that streamlines cancer treatment planning. It integrates disparate data sets, facilitates multidisciplinary discussions among oncology care teams, and automates accreditation processes to enable more informed clinical decisions.

Sonio

Series A in 2023
Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Daye

Series A in 2022
Founded in 2017, Daye is a London-based company dedicated to improving women's gynecological health. It manufactures and markets innovative tampon products, including CBD-infused options for period pain relief, and offers an at-home vaginal microbiome screening kit to detect infections and microbiome disruptions.

Pendulum Systems (formerly Macro-Eyes)

Seed Round in 2022
Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.